Renaissance Technologies LLC acquired a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 111,400 shares of the company's stock, valued at approximately $1,562,000. Renaissance Technologies LLC owned approximately 0.27% of SI-BONE at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Mainstream Capital Management LLC acquired a new stake in shares of SI-BONE in the fourth quarter valued at about $53,000. R Squared Ltd acquired a new stake in SI-BONE in the 4th quarter valued at about $73,000. KLP Kapitalforvaltning AS acquired a new stake in SI-BONE in the 4th quarter valued at about $97,000. Proficio Capital Partners LLC purchased a new position in SI-BONE in the 4th quarter worth approximately $155,000. Finally, AlphaQuest LLC boosted its holdings in shares of SI-BONE by 13,950.6% during the 4th quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock worth $164,000 after purchasing an additional 11,579 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on SIBN. Needham & Company LLC lifted their price objective on SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Truist Financial reissued a "buy" rating and set a $22.00 price target (up previously from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $24.40.
Get Our Latest Stock Analysis on SI-BONE
Insider Transactions at SI-BONE
In other SI-BONE news, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the sale, the senior vice president now directly owns 244,878 shares in the company, valued at $3,462,574.92. This represents a 1.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Anthony J. Recupero sold 3,311 shares of the business's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the transaction, the insider now directly owns 284,555 shares of the company's stock, valued at $4,026,453.25. The trade was a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,776 shares of company stock worth $96,644. 3.90% of the stock is currently owned by insiders.
SI-BONE Trading Down 4.4 %
SI-BONE stock traded down $0.63 during mid-day trading on Wednesday, hitting $13.65. The company's stock had a trading volume of 246,215 shares, compared to its average volume of 359,714. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $19.16. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $579.48 million, a PE ratio of -14.84 and a beta of 1.02. The stock's fifty day moving average is $14.85 and its two-hundred day moving average is $14.66.
SI-BONE (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. The business had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current year.
SI-BONE Company Profile
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
See Also
Before you consider SI-BONE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.
While SI-BONE currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
